Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

Platelet-derived growth factor receptor- α (PDGFRα) is expressed in primary prostate adenocarcinoma and in associated skeletal metastases. Olaratumab is a fully human monoclonal antibody that binds PDGFRα and blocks downstream signalling. This phase II study assessed the efficacy and safety of olaratumab in combination with mitoxantrone and prednisone (M/P) versus M/P alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed after docetaxel.

Source: European Journal of Cancer - December 17, 2018 Category: Cancer & Oncology Authors: Oliver W. Hakenberg, Jose Luis Perez-Gracia, Daniel Castellano, Tomasz Demkow, Tarek Ali, Orazio Caffo, Axel Heidenreich, Wolfgang Schultze-Seemann, Brieuc Sautois, Ivan Pavlik, Amy Qin, Ruslan D. Novosiadly, Ashwin Shahir, Robert Ilaria, Johannes Nippgen Tags: Original Research Source Type: research